Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of a Novel Dual Angiotensin and Endothelin Receptor Antagonist (PS433540) in Subjects With Stage I and II Hypertension.
Latest Information Update: 19 Sep 2011
At a glance
- Drugs Sparsentan (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Pharmacopeia
- 18 Apr 2009 Actual patient number (280) added as reported by ClinicalTrials.gov.
- 15 Apr 2008 Interim results will be reported as a late-breaking abstract at ASH 2008.
- 01 Apr 2008 The expected completion date for this trial is now 1 May 2008, as reported by clinicaltrials.gov.